About this trial
1. Evaluate The impact of early versus late presentation on electrocardiographic ventricular repolarization indices. 2. To assess the association between repolarization indices among early, late presentation in relation to in-hospital ventricular arrhythmias, in-hospital MACE, and 6 months MACE.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
The study will include patients presenting with ST-elevation myocardial infarction (STEMI) who are admitted to the coronary care unit and undergo primary percutaneous coronary intervention (PCI) as the reperfusion strategy. Eligible patients will be adults presenting within the accepted therapeutic window for primary PCI. The final sample will thus represent a consecutive cohort of STEMI patients undergoing primary PCI, allowing assessment of the relationship between total ischemic time and repolarization indices (QTc, Tpe interval, Tpe/QT ratio, etc.), and their subsequent impact on both short- and long-term clinical outcomes.
Trial design
Cohort
Prospective
Treatments tested in this trial
Echocardiography
RadiationSimple, bedsides, non invasive
Treatment groups
Trial outcomes
Primary outcomes
Association between total ischemic time and ventricular repolarization indices
Correlation between total ischemic time (symptom onset to balloon time) and ECG-derived repolarization parameters, including QT interval, corrected QT (QTc), Tpeak-Tend interval, and Tpeak-Tend/QT ratio. Analysis will evaluate linear correlations and threshold effects.
Secondary outcomes
In-hospital ventricular arrhythmias
Occurrence of sustained ventricular tachycardia or ventricular fibrillation documented during index hospitalization.
In-hospital major adverse cardiovascular events (MACE)
Composite of all-cause death, reinfarction (per universal definition of MI), and new or worsening heart failure during index hospitalization.
Six-month major adverse cardiovascular events (MACE)
Composite of cardiovascular mortality, hospitalization for heart failure or recurrent ACS, and target lesion revascularization (TLR) at follow-up.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: